Q4 EPS Estimates for Guardant Health Increased by Analyst

Guardant Health, Inc. (NASDAQ:GH) – Equities researchers at Leerink Partnrs upped their Q4 2024 EPS estimates for shares of Guardant Health in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the company will post earnings per share of ($0.73) for the quarter, up from their prior forecast of ($0.76). The consensus estimate for Guardant Health’s current full-year earnings is ($3.44) per share. Leerink Partnrs also issued estimates for Guardant Health’s Q1 2025 earnings at ($0.62) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.54) EPS and FY2026 earnings at ($2.86) EPS.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The firm had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. During the same period in the previous year, the business earned ($0.73) EPS. Guardant Health’s revenue for the quarter was up 33.9% compared to the same quarter last year.

A number of other equities research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Guggenheim restated a “buy” rating on shares of Guardant Health in a report on Wednesday. Sanford C. Bernstein decreased their price objective on Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. The Goldman Sachs Group raised their price objective on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Leerink Partners reduced their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Fifteen analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $40.60.

Guardant Health Price Performance

Guardant Health stock opened at $47.20 on Thursday. The company’s fifty day moving average price is $34.53 and its 200 day moving average price is $29.26. Guardant Health has a 1 year low of $15.81 and a 1 year high of $49.86.

Hedge Funds Weigh In On Guardant Health

Several institutional investors have recently bought and sold shares of GH. JNBA Financial Advisors acquired a new position in shares of Guardant Health during the third quarter worth about $26,000. R Squared Ltd purchased a new position in Guardant Health in the fourth quarter valued at approximately $26,000. Ashton Thomas Securities LLC purchased a new position in Guardant Health in the third quarter valued at approximately $34,000. Quarry LP purchased a new position in Guardant Health in the second quarter valued at approximately $44,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Guardant Health in the second quarter valued at approximately $71,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. The trade was a 46.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Meghan V. Joyce sold 2,896 shares of Guardant Health stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now directly owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,548 shares of company stock worth $179,782. Company insiders own 5.50% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.